BioSpace News Archive

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Nov. 19, 2020, at 9:30 a.m. Eastern time. A live audio webcast of

Net sales of $111.0 million, an increase of 52% sequentially and within 2% of our 2019 performance US Spinal Implants third quarter net sales increased 19% over the prior year Motion Preservation sales in the U.S. of $5.2 million, an increase of 44% sequentially and over 400% over prior year Entered into an investment and co-development partnership with Neo Medical SA

- Three clinical trials of novel Bicycles ® initiated this quarter, including a Phase IIa for BT1718, a Phase I for BT8009, and a Phase II for THR-149 - Cash was $149.8 million at September 30, 2020, which includes net proceeds received during Q3 from completion of $50.0 million at-the-market (ATM) offering program and initial $15.0 million drawn from debt financing

Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended September 30, 2020; Jakafi ® (ruxolitinib) revenues of $488 million in Q3 2020 (+13% vs Q3 2019); Incyte tightens full year 2020 Jakafi revenue guidance to a range of $1.910 to $1.940 billion Strong momentum behind commercial launches of both Monjuvi ® (tafasitamab-cxix) and Pemazyre ® (pemigatinib) in the U.S.

Asieris Pharmaceuticals recently announced that the Center for Drug Evaluation of the National Medical Products Administration has approved the clinical trial application for its Phase III trial of APL-1202 as single oral agent for the first-line treatment of NMIBC.

The demand within the global bacteriophage market is set to increase at a stellar pace in the times to follow.

Technology is revolutionizing how dentists perform their work, as now lasers are available to repair teeth along with computer-assisted design and manufacturing of implants, crowns, and bridges.

Around 10% of the global population is affected by chronic kidney disease and over 2 million people suffer from end-stage renal disease, which has to be treated by dialysis or kidney transplant.

The demand within the global DNA sequencing market is set to increase alongside advancements in genetic sciences.

Successful patient outcomes are taking over products and services as the key focal point of the healthcare industry.